You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer

Article metrics

Article menu

This article has a correction. Please see:

Clinical/translational cancer immunotherapy
Original research
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer

 

Online download statistics by month:

Online download statistics by month: January 2021 to August 2024

AbstractFullPdf
Jan 2021357357317
Feb 2021472473272
Mar 2021403403146
Apr 2021165165120
May 202112412454
Jun 202120920980
Jul 202114614792
Aug 202115015061
Sep 202111611667
Oct 202114814888
Nov 202112812769
Dec 202112412448
Jan 2022949957
Feb 2022119125112
Mar 2022169174125
Apr 2022250260136
May 202213013692
Jun 202212012173
Jul 20229610059
Aug 202212212882
Sep 2022121123109
Oct 2022182185119
Nov 202212412678
Dec 202212812879
Jan 202310510857
Feb 202315915986
Mar 202316016293
Apr 202310010193
May 202310010271
Jun 2023838455
Jul 202312312583
Aug 202311211372
Sep 202312412979
Oct 2023777766
Nov 202311311365
Dec 2023106106101
Jan 2024115117101
Feb 202411711792
Mar 2024165169151
Apr 2024136136100
May 2024122123105
Jun 2024989780
Jul 2024137139100
Aug 202410310375
Total655266284260